2.58  -0.34 (-11.64%)		03-03 16:00
Open: 2.84 High: 2.84 Volume: 204,459		Pre. Close: 2.92 Low: 2.56 Market Cap: 97(M)

Short term
Mid term
Targets	6-month :	3.21	1-year :	3.53
Resists	First :	2.75	Second :	3.02
Pivot price	2.68
Supports	First :	2.31	Second :	1.92
MAs	MA(5) :	2.86	MA(20) :	2.63
	MA(100) :	4.37	MA(250) :	3.67
MACD	MACD :	-0.1	Signal :	-0.2
%K %D	K(14,3) :	72.5	D(3) :	85.6
RSI	RSI(14): 41.5
52-week	High :	8.53	Low :	1.98

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GNLX ] has closed above bottom band by 35.6%. Bollinger Bands are 63.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 25 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	2.84 - 2.86	2.86 - 2.87
Low:	2.52 - 2.54	2.54 - 2.56
Close:	2.55 - 2.58	2.58 - 2.6

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Tue, 03 Mar 2026
[Form 4] GENELUX Corp Insider Trading Activity - Stock Titan

Mon, 02 Mar 2026
[144] GENELUX Corp SEC Filing - Stock Titan

Fri, 27 Feb 2026
Genelux (NASDAQ:GNLX) Shares Down 2.7% - Should You Sell? - MarketBeat

Wed, 18 Feb 2026
Genelux Corporation to Participate in Upcoming Conferences - Yahoo Finance

Thu, 08 Jan 2026
Genelux Corporation Announces Pricing of $20 Million Public Offering of Common Stock | GNLX Stock News - Quiver Quantitative

Wed, 07 Jan 2026
Genelux Corporation Announces Proposed Public Offering of Common Stock - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	45 (M)
Shares Float	31 (M)
Held by Insiders	10.9 (%)
Held by Institutions	29.8 (%)
Shares Short	3,160 (K)
Shares Short P.Month	3,020 (K)

EPS	-0.88
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.49
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-64.3 %
Return on Equity (ttm)	-123.4 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.75
Qtrly Earnings Growth	0 %
Operating Cash Flow	-23 (M)
Levered Free Cash Flow	-12 (M)

PE Ratio	-2.94
PEG Ratio	0
Price to Book value	5.26
Price to Sales	0
Price to Cash Flow	-4.94

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.